Patents by Inventor Ann Boriack-Sjodin

Ann Boriack-Sjodin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PRMT1 INHIBITORS AND USES THEREOF
    Publication number: 20140288141
    Abstract: Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting PRMT1 activity. Methods of using the compounds for treating PRMT1-mediated disorders are also described.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 25, 2014
    Applicant: Epizyme, Inc.
    Inventors: Kevin Wayne Kuntz, Lorna Helen Mitchell, Gideon Shapiro, Richard Chesworth, Paula Ann Boriack-Sjodin
  • PRMT5 INHIBITORS AND USES THEREOF
    Publication number: 20140228360
    Abstract: Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.
    Type: Application
    Filed: December 20, 2013
    Publication date: August 14, 2014
    Applicant: Epizyme, Inc.
    Inventors: Kenneth W. Duncan, Richard Chesworth, Paula Ann Boriack-Sjodin, Michael John Munchhof
  • PRMT5 INHIBITORS AND USES THEREOF
    Publication number: 20140221345
    Abstract: Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.
    Type: Application
    Filed: December 20, 2013
    Publication date: August 7, 2014
    Applicant: Epizyme, Inc.
    Inventors: Kenneth W. Duncan, Richard Chesworth, Paula Ann Boriack-Sjodin, Michael John Munchhof, Lei Jin
  • Polymer conjugates of mutated neublastin
    Patent number: 8119114
    Abstract: A dimer comprising a mutated neublastin polypeptide coupled to a polymer is disclosed. Such dimers exhibit prolonged bioavailability and, in preferred embodiments, prolonged biological activity relative to wild-type forms of neublastin.
    Type: Grant
    Filed: June 27, 2008
    Date of Patent: February 21, 2012
    Assignee: Biogen Idec MA Inc.
    Inventors: Dinah Wen-Yee Sah, R. Blake Pepinsky, Paula Ann Boriack-Sjodin, Stephan S. Miller, Anthony Rossomando, Laura Silvian
  • HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF
    Publication number: 20100137313
    Abstract: Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.
    Type: Application
    Filed: October 2, 2009
    Publication date: June 3, 2010
    Inventors: Ann Boriack-Sjodin, Daniel Robert Carcanague, Daemian David Dussault, Holia Hatoum-Mokdad, Kenneth Gregory Hull, Georgine Ioannidis, John Irvin Manchester, Helen Maureen McGuire, David Charles McKinney, Suzanne Stokes
  • Substituted Pyrazalones
    Publication number: 20100056505
    Abstract: The invention is related to compounds of formula (I) as antagonists of the TGF? family type I receptors, Alk5 and/or AIk 4, compositions and methods of use. The compounds of formula (I) can be employed in the prevention and/or treatment of diseases such as fibrosis (e.g., renal fibrosis, pulmonary fibrosis, and hepatic fibrosis), progressive cancers, or other diseases for which reduction of TGF? family signaling activity is desirable.
    Type: Application
    Filed: November 21, 2006
    Publication date: March 4, 2010
    Inventors: Wen-Cherng Lee, Mary Beth Carter, Claudio Chuaqui, Kevin Guckian, Edward Lin, Michael J. Choi, Zhan Deng, Paula Ann Boriack-Sjodin, Lihong Sun
  • POLYMER CONJUGATES OF MUTATED NEUBLASTIN
    Publication number: 20080306212
    Abstract: A dimer comprising a mutated neublastin polypeptide coupled to a polymer is disclosed. Such dimers exhibit prolonged bioavailability and, in preferred embodiments, prolonged biological activity relative to wild-type forms of neublastin.
    Type: Application
    Filed: June 27, 2008
    Publication date: December 11, 2008
    Applicant: Biogen Idec MA Inc.
    Inventors: Dinah Wen-Yee Sah, R. Blake Pepinsky, Paula Ann Boriack-Sjodin, Stephan S. Miller, Anthony Rossomando, Laura Silvian
  • Polymer conjugates of mutated neublastin
    Patent number: 7442370
    Abstract: A dimer comprising a mutated neublastin polypeptide coupled to a polymer is disclosed. Such dimers exhibit prolonged bioavailability and, in preferred embodiments, prolonged biological activity relative to wild-type forms of neublastin.
    Type: Grant
    Filed: January 31, 2003
    Date of Patent: October 28, 2008
    Assignee: Biogen Idec MA Inc.
    Inventors: Dinah Wen-Yee Sah, R. Blake Pepinsky, Paula Ann Boriack-Sjodin, Stephan S. Miller, Anthony Rossomando, Laura Silvian
  • Crystal of a Ras-Sos complex and methods of use thereof
    Patent number: 6156526
    Abstract: A detailed three-dimensional structure for the complex formed between Ras and the Son of sevenless (Sos) protein is provided. Crystals of this complex are also included in the invention. The present invention farther provides procedures for identifying agents that can inhibit tumor proliferation through the use of rational drug design predicated on the crystals and crystallographic data disclosed.
    Type: Grant
    Filed: July 21, 1998
    Date of Patent: December 5, 2000
    Assignees: The Rockerfeller University, The Research Foundation of State University of New York
    Inventors: Ann Boriack-Sjodin, S. Mariana Margarit, Dafna Bar-Sagi, Philip Cole, John Kuriyan
  • Crystal of a Ras-Sos complex
    Patent number: 6117663
    Abstract: A detailed three-dimensional structure for the complex formed between Ras and the Son of sevenless (Sos) protein is provided. Crystals of this complex are also included in the invention. The present invention further provides procedures for identifying agents that can inhibit tumor proliferation through the use of rational drug design predicated on the crystals and crystallographic data disclosed.
    Type: Grant
    Filed: July 19, 1999
    Date of Patent: September 12, 2000
    Assignees: The Rockefeller University, The Research Foundation of State University of New York
    Inventors: Ann Boriack-Sjodin, S. Mariana Margarit, Dafna Bar-Sagi, Philip Cole, John Kuriyan